SCHEMBL771298

SCHEMBL771298

COC(=O)C1COC(c2ccccc2)=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6708480 1.00
SCHEMBL12245522 1.00
SCHEMBL21825776 0.87
SCHEMBL21825774 0.87
SCHEMBL13038277 0.86
SCHEMBL25012007 0.85
SCHEMBL2221193 0.85
SCHEMBL1338762 0.85 MEN1 (0.56)
SCHEMBL1338765 0.85 MEN1 (0.56)
SCHEMBL1336590 0.85 NPC1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
EP-3862083-B1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND GLACEUM INC (KR) 2023-03-08 EP disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-11420988-B2 Catalyst for asymmetric hydrogenation of compound containing carbon double bond GLACEUM, INC. (KR) 2022-08-23 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-20210395282-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND GLACEUM, INC. (KR) 2021-12-23 US disclosed
EP-3862083-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND Glaceum, Inc. (KR) 2021-08-11 EP disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
WO-2020071818-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND 주식회사 글라세움 2020-04-09 WO disclosed
US-20090186855-A1 COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-23 US disclosed
US-7550501-B2 Compounds and methods for treating toll-like receptor 2-related diseases and conditions EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-23 US disclosed
US-7550501-B2 Compounds and methods for treating toll-like receptor 2-related diseases and conditions EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-23 US disclosed
US-20070167409-A1 Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions EISAI CO., LTD. (JP) 2007-07-19 US disclosed
US-20070167409-A1 Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions EISAI CO., LTD. (JP) 2007-07-19 US disclosed
US-7202234-B2 Compounds and methods for treating Toll-like receptor 2-related diseases and conditions EISAI CO., LTD. (JP) 2007-04-10 US disclosed
US-7202234-B2 Compounds and methods for treating Toll-like receptor 2-related diseases and conditions EISAI CO., LTD. (JP) 2007-04-10 US disclosed
US-5578627-A FOR TREATING CEREBRAL CIRCULATORY DISORDER, HEAD INJURY SEQUELAE AND/OR EPILEPSY TOYAMA CHEMICAL CO., LTD. (JP) 1996-11-26 US disclosed
EP-0665226-A1 NOVEL 1,2-BENZISOXAZOLE DERIVATIVE OR SALT THEREOF, AND BRAIN PROTECTIVE AGENT COMPRISING THE SAME TOYAMA CHEMICAL CO., LTD. (JP) 1995-08-02 EP disclosed
US-4702864-A ANTIINFLAMMATORY AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-27 US disclosed